94 results about "Lactate dehydrogenases" patented technology

The invention relates to a method for determining the content of blood ammonia, and also the reagent kit for blood ammonia diagnosis. The reagent kit comprises cushioning solution, adenosine triphosphate, phosphoenolpyruvate phosphatase, deacidized type coenzyme, ammonia kinase, pyruvate kinase, lactate dehydrogenase, and stabilizer. By mixing sample and reagent of a predetermiend volumetric ratio, generating coupling reaction between them, subjecting the final reactant to biochemiscal analyser, the main wavelength absorbancy variance ratio (speed) can be detected, and the blood ammonia content can thus be measured. The method of the invention can be used to obtain the needed measurement result purely through biochemical analytic instruments, and advantages of the method include higher sensibility, better accuracy, less susceptibility to contamination of internal or external materials, and easy application.

This invention relates to a test kit for diagnosing hepatic and biliary diseases. The test kit has such advantages as high stability, high accuracy and high sensitivity. The test kit comprises two reagents. Reagent 1 comprises oxidized thio coenzyme, buffer solution, preservative, and anti-interference agent. Reagent 2 comprises 3alpha-HSD, reduced coenzyme, buffer solution, preservative, complexing agent, polymer accelerator, stabilizer, and one of formate dehydrogenase-formic acid-NAD, glutamate dehydrogenase-glutamic acid-oxidized nicotinamide coenzyme, glucose-6-phosphate dehydrogenase-glucose-oxidized nicotinamide coenzyme, glucose dehydrogenase-xylose-oxidized nicotinamide coenzyme, lactate dehydrogenase-alpha-ketoglutarate-oxidized nicotinamide coenzyme, and glycerol dehydrogenase-ethylene glycol-oxidized nicotinamide coenzyme.

The invention relates to an L- lactate dehydrogenase gene, and the nucleotide sequence represents as SEQ ID NO. 1. The invention further provides an expression vector with the gene, a recombinant Escherichia coli, a recombinant Escherichia coli construction method and the application thereof during phenylpyruvic acid conversion and (S)-2-hydroxy-3-phenylpropionic acid synthesis. The method includes after performing codon optimization on (Bacillus megaterium Z2013513) CCTCC NO. M2013244 L- lactate dehydrogenase gene, constructing the expression vector, inducing expression of the Escherichia coli, and obtaining the L-PLA production strain with simple culture condition, convenience for usage and wide application. The yield for the recombinant Escherichia coli converting the L-PLA in whole-cell and single-batch manners is 27.13mmol / L, the converting rate is 77.5%, and the basis is provided for increasing the L-PLA yield and producing rate for subsequent fermentor continuous feeding.

[PROBLEMS] To provide lipase activity determination reagents which function by an enzymatic method. The reagents are easy to use in an ordinary clinical examination, have excellent handleability, and are excellent in accuracy and reproducibility. [MEANS FOR SOLVING PROBLEMS] Lipase activity is determined with any of reagents which comprise a low-concentration buffer and a diglyceride dissolved therein. The diglyceride is used as a substrate for lipase, whereby the liquid reagents can have long-term storage stability. One of the reagents converts a monoglyceride yielded by a lipase reaction into glycerol with the aid of monoglyceride lipase, and further contains glycerol kinase, pyruvate kinase, lactate dehydrogenase, reduced NAD, ATP, and phosphoenol pyruvate. Another reagent converts a monoglyceride yielded by a lipase reaction into glycerol with the aid of monoglyceride lipase, and further contains glycerol kinase, glucose, ADP-dependent hexokinase, glucose-6-phosphate dehydrogenase, oxidized NAD or oxidized NADP, and ATP. A further reagent converts a monoglyceride yielded by a lipase reaction into glycerol with the aid of monoglyceride lipase, and further contains glycerol kinase, glycerol-3-phosphate oxidase, peroxidase, and a dye which colors in the presence of hydrogen peroxide.

The invention provides an antibody against lactate dehydrogenase of plasmodium vivax, which is a monoclonal antibody or polyclonal antibody specific to proteins shown in SEQ ID NO: 2. More preferably, the monoclonal antibody or polyclonal antibody is obtained by using a fusion protein formed by the protein shown in SEQ ID NO: 2 and the known label as an antigen immune animal; the monoclonal antibody is produced by a hybridoma cell strain of which the collection number is CGMCC No.3897 or No.3898. The invention also provides a hybridoma cell strain producing the antibody against the lactate dehydrogenase of plasmodium vivax, a preparation method and use of the antibody against the lactate dehydrogenase of plasmodium vivax, a related immunoassay method, a kit prepared from the antibody, etc. The antibody against the lactate dehydrogenase of plasmodium vivax can specifically detect the lactate dehydrogenase of plasmodium vivax, can be applied to specificity detection of vivax infection, has the advantages of high specificity, sensitive response and low cost, and is applicable to high-throughput detection.

The invention provides a discriminating method of the inherited characteristics of Kyrgyzstan cichlidae and application thereof, in particular to a discriminating method of the inherited characteristics of a new specie-Kyrgyzstan cichlidae tilapia (an intergeneric distant hybridization and selective breeding offspring of tilapia nilotica and sarotherodon melanotheron) suitable for mariculture andapplication thereof. The discriminating method comprises the following steps of: detecting isoenzymes, karyotypes and/or microsatellite markers of fishes to be detected; and comparing a detection result with a positive control or a standard substance so as to determine or judge whether the detected fishes are Kyrgyzstan cichlidae tilapias or not, wherein the isoenzymes are lactate dehydrogenases.The discriminating method can reliably and accurately discriminate the Kyrgyzstan cichlidae tilapias.

The invention relates to a chicken Eimeria acervulina immunoregulation type DNA vaccine, which belongs to the technical field of biological veterinary medicines. The molecular biology technology is used for connecting lactate dehydrogenase genes of schizont antigen of the first generation of chicken Eimeria acervulina and chIL-2 genes in series to construct a fusion expressing vaccine pVAX-LDH-IL-2. The vaccine comprises a plurality of T cell immune response elements, thus preventing and curing chicken coccidiosis effectively.

The invention discloses a soil remediation agent as well as a preparation method and a using method thereof. The soil remediation agent is synthesized and prepared from municipal domestic sludge aminoacid and magnetic Fe3O4/CaFe-LDH (Lactate Dehydrogenase). In the soil remediation agent, the amino acid is adsorbed between hydrotalcite layers or on a hydrotalcite layer, on one hand, the amino acidcan be protected from being infected by bacteria, and the amino acid can be used as soil base fertilizer for application; on the other hand, multiple heavy metal can be adsorbed due to the unique structure characteristics of hydrotalcite, the bio-availability of soil heavy metal can be reduced, meanwhile, used hydrotalcite can be conveniently recycled and reutilized due to magnetism, and soil hardening or deterioration of physic-chemical properties cannot be caused due to long-term fertilization, so that the soil remediation agent can be applied securely. Raw materials applied by the technology are waste or cheap and easy-to-obtain compounds, and the preparation and the application are also very convenient; on one hand, necessary nutrients for metabolism of plants can be provided by the obtained soil remediation agent, on the other hand, aeolian sandy soil can be stabilized and improved by growth of the plants in return, and finally, the purposes of remediating the aeolian sandy soiland greening the environment can be achieved.

The invention discloses a functional yoghurt product with the inhibitory activity of alpha-glucosidase and tyrosinase, and a preparation method thereof. The functional yoghurt product is characterizedby performing superfine crushing on fleeceflower root and kudzuvine root, then performing mixing with water, skim milk powder and sugar in a certain proportion, and performing a process of stirring and uniform mixing, filtering, colloid mill emulsification, sterilization, cooling, Lactobacillus plantarum, Lactobacillus acidophilus and Streptococcus thermophilus starter addition, uniform mixing, filling, fermentation, cooling and post-ripening to obtain the yoghurt product with the inhibitory activity of alpha-glucosidase and tyrosinase and the anti-fatigue function. The advantages are that the content of polyphenols and flavonoid aglycones can be significantly increased, the activity of serum glutathione peroxidase, superoxide dismutase and lactate dehydrogenase in mice is increased, andthe content of malondialdehyde and urea nitrogen is reduced.

The present disclosure provides non-naturally occurring c1 microorganisms useful for the production of lactate and related compositions, as well as methods for the biologically production of lactate. In specific embodiments, the present disclosure provides non-naturally occurring methanotrophic bacteria which are useful for producing lactate from c1 substrates.

An alpha-acetolactate decarboxylase powder is prepared from the alpha-acetolactate decarboxylase liquid and the spray-frying protector composed of mycose, xanthan gum, sodium alginate and dextrin through spray drying. Its advantage is high stability.

The invention belongs to the field of biological medicines, and relates to an application of baicalin in preparation of a medicine for preventing and/or treating asymptomatic hyperuricemia and/or uricacid nephropathy. Based on animal and cell experiments, the effect of baicalin on hyperuricemia nephropathy is studied, and the result shows that baicalin can inhibit the activity of xanthine oxidase, inhibit uric acid generation, reduce the serum uric acid level of mice with uric acid nephropathy and remarkably improve the renal function of the mice. The baicalin inhibits damage of sodium uratecrystals to rat renal tubular epithelial cells by reducing secretion of TNF alpha, IL-1beta, lactate dehydrogenase and NO.

The invention provides an application of an anoectochilus roxburghii extract in preparation of drug for preventing and/or treating D-galactosamine-induced acute liver injury of mice and belongs to thetechnical field of medicines. Experiments prove that the anoectochilus roxburghii extract can remarkably improve D-galactosamine-induced acute liver injury symptoms for the first time, the specific performance is that the necrosis areas of liver cells of mice are obviously decreased, inflammatory cell infiltration, ballooning and fatty degeneration of liver cells are alleviated, the lobular structure of liver tends to be regular, and the arrangement of hepatic cords are regular and tidy. In terms of biochemical indexes, the anoectochilus roxburghii extract can obviously reduce the increased activity of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and malondialdehyde due to the D-galactosamine-induced acute liver injury. A foundation is laid for further development and utilization of anoectochilus roxburghii as a natural medicine raw material, in particular as a drug for preventing and/or treating liver diseases.

The invention relates to a liver protecting and calming pill which has the efficacy of clearing heat and promoting diuresis, benefiting liver and removing blood stasis, soothing liver and relieving pain, removing jaundice and lowering glutamic-pyruvic transaminase, and is suitable for treating acute hepatitis and chromic hepatitis and the active components of which consists of the medicinal materials of stringy stonecrop, giant knotweed, red sage root and ganoderma lucidum, and a preparation method thereof. The liver protecting and calming pill prompts an organism to play the normal immunologic role, start a liver self-healing system, block autoimmune reaction and strength physique and anti-virus ability; recovers the normal detoxification function of the liver to cause normal operation of human body; resists liver damage to effectively inhibit the increase of serum glutamic-pyruvic transaminase (SGPT), serum glutamic-oxaloacetic transaminase (SGOT) and lactate dehydrogenase (LDH); and increases hemoglobin to obviously increase the Hb content of blood plasma. The liver protecting and calming pill keeps stable blood-drug level and fully play the drug effect according to the theory of long-term administration for liver disease and the 'sluggish characteristic of pills' .

The invention discloses a traditional Chinese medicine composite used for releasing fatigue as well as preparation method of the traditional Chinese medicine composite. The traditional Chinese medicine composite disclosed by the invention takes Maca which has various functions of improving fertility, resisting fatigue, improving sexual performance, antioxidation, inhibiting hyperplasia of prostate, alleviating menopausal syndrome, strengthening immunity combined with American ginseng extract, rhizome chuanxiong extract, morinda officinalis extract, tuber onion seed extract and tangerine peel extract. The traditional Chinese medicine compound has the functions of antioxidation and antifatigue, can lower the levels of lactate dehydrogenase and serum urea, improve succinate dehydrogenase activity of muscles, effectively relief uncomfortable feeling after exercise, such as limb weakness, tiredness and muscle soreness. The invention also provides a traditional Chinese medicine preparation containing the traditional Chinese medicine composite and a preparation method of the traditional Chinese medicine preparation.

The invention provides an intestinal flora related to immune recovery and application thereof. As found in the invention for the first time, specific intestinal bacteria species have the effect of promoting body immune recovery. A biomarker related to immune recovery provided by the invention comprises 32 intestinal bacteria species, dextral lactate dehydrogenase and 18 lactic acid bacteria species. By utilizing the biomarker, risk assessment can be carried out on immune recovery prognosis after immune impairment of a patient, accuracy, sensitivity and specificity are high, sample collection is convenient, no body injury is generated, detection is convenient and fast, regular detection can be carried out, and the intestinal species can be used to develop preventive and therapeutic productsand assist the treatment of patients with impaired immune functions in order to reduce the incidence rate of poor immune recovery.

The invention discloses a synthesis method of 3[alpha],7[beta]-dihydroxy-5[alpha]-cholanic acid. The method takes allochenodeoxycholic acid as an initial raw material and includes the following steps: adding phosphate buffer, nicotinamide adenine dinucleotide phosphate, lactate dehydrogenase, 7-[alpha]hydroxysteroid dehydrogenase and sodium pyruvate, performing reaction, and performing cooling after enzyme was inactivated through high temperature; additionally adding L-sodium malate, malate dehydrogenase and 7-[beta]hydroxysteroid dehydrogenase to react, and performing cooling to room temperature after the enzyme was inactivated through high temperature; and obtaining the 3[alpha],7[beta]-dihydroxy-5[alpha]-cholanic acid through filtration, washing and drying. The overall process of the method includes the oxidation and reduction steps of the allochenodeoxycholic acid and the synthesis of the 3[alpha],7[beta]-dihydroxy-5[alpha]-cholanic acid. The whole reaction of the method is conducted in an aqueous solution without using organic solvents; the method is simple in technology and easy to operate; and the purity of the obtained 3[alpha],7[beta]-dihydroxy-5[alpha]-cholanic acid can reach more than 98.5%, and the obtained 3[alpha],7[beta]-dihydroxy-5[alpha]-cholanic acid can be used as samples of pharmaceutical properties such as toxicology and pharmacology in pharmaceutical research institutions and can also be used as impurity reference substances during quality research of ursodeoxycholic acid.

The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor γ nuclear translocation, and inhibit nuclear transcription factor NF-κB nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.

The invention discloses a composite vehicle air conditioning filter core and a preparation method thereof. The preparation method includes: 1), soaking a carbon fiber felt in an H2SO4 solution, washing the carbon fiber felt with ethanol and water and then drying the same; dissolving LDH (lactate dehydrogenase)/g-C3N4 in water to obtain dispersing fluid, placing the dried carbon fiber felt in the LDH/g-C3N4 dispersing fluid for soaking for 10 minutes, washing the carbon fiber felt with water prior to drying the same, then soaking the carbon fiber felt in 1wt% of a PVA (polyvinyl acetate) solution for 1 hour, and washing the same with water prior to drying the same; 3), repeating the step 2) for multiple times, soaking an obtained loaded carbon felt in a glutaraldehyde solution for 1 hour, and washing the loaded carbon felt with water prior to drying the same to obtain carbon felt loaded LDH/g-C3N4 composite filter core. The filter core is composed of hydrotalcite LDH and graphite phasecarbon nitride g-C3N4, so that stacking agglomeration of LDH can be effectively reduced, the active area of g-C3N4 is increased, and catalytic efficiency and adsorption efficiency of composites are enhanced; through the load of the carbon fiber felt, the loading material has good adsorption effect and stability.